Filter News

BioSpecifics Technologies Corporation To Present At The 2016 UBS Global Healthcare Conference

Published: May 18, 2016

LYNBROOK, N.Y., May 18, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.   

A live webcast of the presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or at https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=103_Q7R0QTK

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe. Endo has the following partnerships outside the U.S. for these two indications: Swedish Orphan Biovitrum AB (Sobi) has marketing rights for Xiapex® (the European tradename for XIAFLEX) in 71 Eurasian and African countries, Actelion Pharmaceuticals Ltd. (Actelion) has marketing rights in Canada and Australia and Asahi Kasei Pharma Corporation (Asahi) has marketing rights in Japan. Sobi is currently selling Xiapex in Europe for the treatment of Dupuytren's contracture and Peyronie's disease. Asahi has received regulatory approval and is currently selling XIAFLEX for the treatment of Dupuytren's contracture in Japan. Actelion has received regulatory approval for and is currently selling XIAFLEX in Canada and Australia for the treatment of Dupuytren's contracture. The XIAFLEX development pipeline includes several additional promising indications. Endo is currently managing the development of cellulite, adhesive capsulitis, canine lipoma, lateral hip fat and plantar fibromatosis. BioSpecifics is currently managing the clinical development of human lipoma and plans to initiate clinical development of uterine fibroids in the second half of 2016. For more information, please visit www.biospecifics.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-2016-ubs-global-healthcare-conference-300270564.html

SOURCE BioSpecifics Technologies Corp.

Back to news